Paper Details

  1. Home
  2. Paper Details

Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity.

Author: DarekarAmanda, MalhotraBimal K, SanoYamato, ShahinMohamed, ShojiSatoshi, SweeneyKevin

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study aimed to characterize the population pharmacokinetics of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of fesoterodine, in pediatric patients with overactive bladder (OAB) or neurogenic detrusor overactivity (NDO) following administration of fesoterodine.
Paper Details　
Original Abstract of the Article :
Fesoterodine is a muscarinic receptor antagonist approved for the treatment of overactive bladder (OAB) in adults and neurogenic detrusor overactivity (NDO) in pediatric patients. This work aimed to characterize the population pharmacokinetics of 5-hydroxymethyl tolterodine (5-HMT, the active metabo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10175358/

データ提供：米国国立医学図書館（NLM）

Fesoterodine: A Desert Oasis for Children with Neurogenic Detrusor Overactivity

Neurogenic detrusor overactivity (NDO), a condition that affects bladder control, can significantly impact a child's quality of life. Imagine NDO as a desert sandstorm, causing frequent urination and discomfort. This study investigates the pharmacokinetics and pharmacodynamics of fesoterodine, a drug used to treat overactive bladder, in pediatric patients with NDO. Think of fesoterodine as a desert healer, working to restore balance and control to the bladder.

A Desert Oasis of Understanding: Uncovering the Pharmacokinetic and Pharmacodynamic Properties of Fesoterodine

The study uses population pharmacokinetic and pharmacodynamic modeling to characterize the behavior of fesoterodine in pediatric patients with NDO. This approach helps researchers understand how the drug is absorbed, distributed, metabolized, and eliminated by the body, and how it affects the bladder function. This research provides valuable data for doctors, allowing them to make more informed decisions about fesoterodine dosage and treatment strategies for children with NDO.

Navigating the Desert of Bladder Control: A Journey Toward Better Health

This study highlights the importance of understanding the pharmacokinetic and pharmacodynamic properties of drugs, especially in pediatric populations. It emphasizes the need for individualized care, ensuring that treatment is tailored to each child's unique needs and characteristics. This research serves as a reminder that even in the challenging desert of NDO, there is hope for a healthier future.

Dr. Camel's Conclusion

This study provides valuable insights into the use of fesoterodine in pediatric patients with NDO. It underscores the importance of careful drug selection and dosage adjustments based on individual patient characteristics, ensuring optimal treatment outcomes for children with this condition.
Date :
  1. Date Completed 2023-05-17
  2. Date Revised 2023-09-02
Further Info :

Pubmed ID

36892754

DOI: Digital Object Identifier

PMC10175358

Related Literature

Article Analysis
・Effects of fesoterodine
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.